The page is the record's research on the issuer — no analyst, no rating, no view. # Aktis Oncology, Inc. (NASDAQ: AKTS) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Aktis Oncology, Inc., listed on NASDAQ under ticker AKTS, with ISIN US01021M1045. The record holds no LEI for the issuer, as no GLEIF record with the exact legal name in jurisdiction US-DE exists. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The issuer is listed and not halted. ## The disclosure read The record holds 59 filings in the twelve months to 2026-11-08, across 23 filing days. The filings comprise 30 directors' dealings, 17 regulatory filings, 6 results, 4 prospectuses, 1 ad hoc notice and 1 director change. The median gap between filing days is 3.0 days. The latest filing is dated 2026-09-24 and is of type directors' dealings, 45 days before the record date. The NASDAQ median gap between filing days is 6.0 days, with a median of 52 filings and a median latency of 5.0 days across 4,359 issuers. The sector median gap is 6.0 days, with a median of 63.0 filings and a median latency of 4.0 days across 526 issuers. ## Auditor The auditor is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and the auditor's location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no delisting and no name change. The record holds listing lines dated 2026-01-07 and 2026-01-08. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as exchange tier transfers are not EDGAR filings. The issuer is listed and not halted. ## Orderability The outcome is not determinable, as the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations page. ## Open research No openly published research notes were found on the record. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The record holds sealed years 2024, 2025 and 2026 for the issuer. The earliest sealed date for the market is 2021-01-04. The live record began on 2026-09-12. ## Sources 7 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0002035832.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/AKTS (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/AKTS (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/AKTS · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp